Grifols (GIKLY) Non-Current Debt (2009 - 2025)
Grifols (GIKLY) posted Non-Current Debt of $10.6 billion for Q4 2025, up 4.34% quarter-over-quarter from $10.1 billion in Q4 2024, and up 4.34% year-on-year from $10.1 billion in Q4 2024.
Grifols (GIKLY) Non-Current Debt (2009 - 2025) Analysis & Trends
Grifols (GIKLY) has reported Non-Current Debt for 16 consecutive years, with $10.6 billion the latest figure, recorded in Q4 2025.
- Non-Current Debt for Q4 2025 came in at $10.6 billion, up 4.34% year-over-year; the trailing twelve-month figure through Dec 2025 was $10.6 billion (up 4.34% YoY), and the FY2025 annual result was $10.6 billion, up 4.34% from the prior year.
- Non-Current Debt was $10.6 billion for Q4 2025 at Grifols, up from $10.1 billion in the prior quarter.
- Over five years, Non-Current Debt peaked at $10.6 billion in Q4 2025 and troughed at $875.9 million in Q4 2023.
- Average Non-Current Debt over 5 years is $8.2 billion, with a median of $10.1 billion recorded in 2024.
- Year-over-year, Non-Current Debt tumbled 91.48% in 2023 and surged 1057.91% in 2024.
- Over 5 years, Non-Current Debt stood at $8.9 billion in 2021, then rose by 15.65% to $10.3 billion in 2022, then sank by 91.48% to $875.9 million in 2023, then soared by 1057.91% to $10.1 billion in 2024, then climbed by 4.34% to $10.6 billion in 2025.
- Per Business Quant data, the three most recent Non-Current Debt figures were $10.6 billion in Q4 2025, $10.1 billion in Q4 2024, and $875.9 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 39.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 37.53 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 64.53 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -24.45 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 46.67 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 51.89 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 20.86 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 60.57 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | 10.58 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.58 Bn |
| Dec 31, 2024 | 10.14 Bn |
| Dec 31, 2023 | 875.89 Mn |
| Dec 31, 2022 | 10.28 Bn |
| Dec 31, 2021 | 8.89 Bn |
| Dec 31, 2020 | 7.87 Bn |
| Sep 30, 2020 | 7.86 Bn |
| Mar 31, 2020 | 7.58 Bn |
| Dec 31, 2019 | 66.39 Mn |
| Sep 30, 2019 | 7.68 Bn |
| Dec 31, 2018 | 90.12 Mn |
| Sep 30, 2018 | 7.11 Bn |
| Jun 30, 2018 | 7.19 Bn |
| Mar 31, 2018 | 8.43 Bn |
| Dec 31, 2017 | 6.95 Bn |
| Jun 30, 2017 | 6.64 Bn |
| Dec 31, 2016 | 33.44 Mn |
| Sep 30, 2016 | 5.01 Bn |
| Jun 30, 2016 | 5.10 Bn |
| Mar 31, 2016 | 28.34 Mn |